Clinical Insights on Hepatotoxicity Associated with Ribociclib in Breast Cancer Patients: A Multi-Center Analysis
Clinical Scorecard: Clinical Insights on Hepatotoxicity Associated with Ribociclib in Breast Cancer Patients: A Multi-Center Analysis
At a Glance
Category Detail
Condition Hepatotoxicity associated with ribociclib in HR+/HER2- breast cancer patients Key Mechanisms Inhibition of CDK4/6 leading to potential hepatotoxicity via CYP3A4 metabolism and oxidative stress Target Population Patients with advanced hormone-receptor-positive and HER2-negative breast cancer Care Setting Multi-center hospitals treating breast cancer
Key Highlights
9.2% of patients developed hepatotoxicity from ribociclib Grade 3-4 hepatotoxicity associated with decreased overall survival (OS) One-year OS rate: 90% for grade 1-2, 76% for grade 3-4 hepatotoxicity Management may include corticosteroids and continued hormonal therapy Median onset of hepatotoxicity: 13 weeks post ribociclib initiation Guideline-Based Recommendations
Diagnosis
Utilize CTCAE v5.0 for grading liver injury Conduct hepatobiliary ultrasonography and serological markers testing Management
Continue hormonal therapy in patients with hepatotoxicity Consider corticosteroids for severe cases Monitoring & Follow-up
Regular liver function tests during ribociclib treatment Assess liver function restoration before re-challenging with CDK 4/6 inhibitors Risks
Potential for autoimmune hepatitis and oxidative liver injury Increased risk of hepatotoxicity with ribociclib use Patient & Prescribing Data
Patients aged over 18 with metastatic HR+/HER2- breast cancer
Ribociclib is effective but requires monitoring for hepatotoxicity
Clinical Best Practices
Monitor liver enzymes regularly in patients receiving ribociclib Educate patients on signs of hepatotoxicity Implement a structured follow-up plan for patients with liver injury References
